莫米松

莫米松
臨床資料
商品名（英語：Drug nomenclature）	Nasonex, Asmanex, Elocon, othersMometasone Use During Pregnancy. Drugs.com. 14 February 2020 [1 April 2020]. （原始內容存檔於2020-10-26）.</ref>
其他名稱	LAS-41002, 9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
給藥途徑	Topical, inhalation (nasal spray)
藥物類別（英語：Drug class）	Corticosteroid; Glucocorticoid
ATC碼	D07AC13 (WHO) R01AD09, R03BA07;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 歐：Rx-only; 美：處方藥（℞-only）;
藥物動力學數據
生物利用度	Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone
血漿蛋白結合率	98% to 99%
藥物代謝	Liver
生物半衰期	5.8 hours
識別資訊
	IUPAC命名法 (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate; ;
CAS號	105102-22-5
PubChem CID	441335; 441336;
DrugBank	DB00764 ; DB14512;
ChemSpider	390090 ; 390091;
UNII	8HR4QJ6DW8; 04201GDN4R;
KEGG	D08227; D00690;
ChEBI	CHEBI:6970 ; CHEBI:47564;
ChEMBL	ChEMBL1201404 ; ChEMBL1161;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID4023333 ;
ECHA InfoCard	100.125.600
化學資訊
化學式	C22H28Cl2O4 for mometasone; C27H30O6Cl2 as furoate
3D模型（JSmol（英語：JSmol））	交互式圖像; 交互式圖像;
	SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C; ; CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C;
	InChI InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 ; Key:QLIIKPVHVRXHRI-CXSFZGCWSA-N ; ; InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1; Key:WOFMFGQZHJDGCX-ZULDAHANSA-N;

莫米松（Mometasone），是一種糖皮質激素，用於治療某些皮膚病、花粉熱和哮喘^[4] ^[5] ^[6]，具體用於預防哮喘發作（非治療）。^[4]可應用於皮膚、吸入或鼻部。^[4]^[5]^[6]^[7]

莫米松用於哮喘的常見副作用包括鵝口瘡等^[4]，因此建議使用後漱口，^[4]長期使用可能會增加患青光眼和白內障的風險。^[4]應用於鼻部的常見副作用包括上呼吸道感染和流鼻血。^[6]應用於皮膚時的常見副作用包括痤瘡、皮膚萎縮和瘙癢。^[5]它通過減少炎症起作用。^[4]

糠酸莫米松於1981年獲得專利，並於1987年開始醫用。^[8]它在世界衛生組織的基本藥物清單上^[9]，可作為通用藥物使用。 ^[10]2017年，它是美國第197種最常用的處方藥，共開出超過200萬張處方。^[11] ^[12]

參考資料

^ Nasonex- mometasone furoate spray, metered. DailyMed. 26 January 2011 [19 June 2022]. （原始內容存檔於2022-11-05）.
^ https://www.ema.europa.eu/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa/00002085/202005_en.pdf ^[裸網址]
^ Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology. November 2007, 64 (5): 698–705. PMC 2203259 . PMID 17509041. doi:10.1111/j.1365-2125.2007.02919.x.
^ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 ^4.5 ^4.6 Mometasone Furoate Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. （原始內容存檔於2016-10-07）（英語）.
^ ^5.0 ^5.1 ^5.2 Mometasone Furoate topical Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. （原始內容存檔於2020-08-05）（英語）.
^ ^6.0 ^6.1 ^6.2 Mometasone Furoate eent Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. （原始內容存檔於2016-04-30）.
^ Mometasone. DrugBank. [30 April 2020]. （原始內容存檔於2019-06-29）.
^ Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 488. ISBN 9783527607495.
^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.
^ British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 265. ISBN 9780857113382.
^ The Top 300 of 2020. ClinCalc. [11 April 2020]. （原始內容存檔於2020-03-18）.
^ Mometasone - Drug Usage Statistics. ClinCalc. [11 April 2020]. （原始內容存檔於2021-01-27）.

[Nasonex_FDA_label-1] Nasonex- mometasone furoate spray, metered. DailyMed. 26 January 2011 [19 June 2022]. （原始內容存檔於2022-11-05）.

[2] ttps://www.ema.europa.eu/documents/psusa/mometasone-list-nationally-authorised-medicinal-products-psusa/00002085/202005_en.pdf ^[裸網址]

[3] Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. British Journal of Clinical Pharmacology. November 2007, 64 (5): 698–705. PMC 2203259 . PMID 17509041. doi:10.1111/j.1365-2125.2007.02919.x.

[AHFS2019Asthma-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 ^4.5 ^4.6 Mometasone Furoate Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. （原始內容存檔於2016-10-07）（英語）.

[AHFS2019Skin-5] 5.0 ^5.1 ^5.2 Mometasone Furoate topical Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. （原始內容存檔於2020-08-05）（英語）.

[AHFS2019Nose-6] 6.0 ^6.1 ^6.2 Mometasone Furoate eent Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [11 March 2019]. （原始內容存檔於2016-04-30）.

[7] Mometasone. DrugBank. [30 April 2020]. （原始內容存檔於2019-06-29）.

[Fis2006-8] Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 488. ISBN 9783527607495.

[WHO22nd-9] World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.

[BNF76-10] British national formulary : BNF 76 76. Pharmaceutical Press. 2018: 265. ISBN 9780857113382.

[11] The Top 300 of 2020. ClinCalc. [11 April 2020]. （原始內容存檔於2020-03-18）.

[12] Mometasone - Drug Usage Statistics. ClinCalc. [11 April 2020]. （原始內容存檔於2021-01-27）.

[2]

[1]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]